| HOME >> MEDICINE >> TECHNOLOGY |
Interest expense (266) - (266)
Loss before non-controlling
interest in Symphony Allegro,
Inc. (16,273) 1,378 (14,895)
Loss attributed to
non-controlling interest
in Symphony Allegro, Inc. 3,100 - 3,100
Net loss $(13,173) $1,378 $(11,795)
Basic and diluted net loss per
share $(0.42)
Shares used to compute basic
and diluted net loss per share 31,097
[1] Reflects operating results in accordance with U.S. generally accepted
accounting principles (or GAAP).
[2] Represents share-based compensation expense.
[3] Non-GAAP amounts exclude share-based compensation expense.
Alexza Pharmaceuticals, Inc.
(a development stage company)
Condensed Consolidated Statements of Operations
(unaudited, in thousands except per share data)
Three Months Ended
December 31, 2006
GAAP [1] Difference [2] Non-GAAP [3]
Revenue $- $- $-
Operating expenses
Research and development 10,514 (522) 9,992
General and administrative 3,339 (288) 3,051
Total operating expenses 13,853 (810) 13,043
Loss from operations (13,853) 810 (13,043)
Interest and other income, net 658 - 658
Interest expense (132) - (132)
Loss before non-controlling
interest in Symphony Alleg
'/>"/>
| SOURCE Alexza Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |